{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Kezar Life Sciences, Inc.
Is Kezar Life Sciences, Inc. technically bullish or bearish?
As of June 2, 2025, the market trend is mildly bearish, indicated by mixed signals from the MACD and KST showing mild bullishness, while Bollinger Bands and daily moving averages reflect bearish trends.
Who are in the management team of Kezar Life Sciences, Inc.?
As of March 2022, the management team of Kezar Life Sciences, Inc. includes Dr. Jean-Pierre Sommadossi (Independent Chairman), Dr. Christopher Kirk (President and Chief Scientific Officer), and CEO John Fowler, along with several independent directors. They oversee the company's strategic direction and operations.
What does Kezar Life Sciences, Inc. do?
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for autoimmune disorders and cancer. It has a market cap of approximately $29.88 million and reported a net profit loss of $17 million as of March 2025.
How big is Kezar Life Sciences, Inc.?
As of Jun 18, Kezar Life Sciences, Inc. has a market capitalization of 29.88 million, categorizing it as a Micro Cap company, with total assets of 144.68 million and shareholder's funds of 116.92 million. The company reported net sales of 0.00 million and a net profit of -78.64 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
